SECONDARY MYELOFIBROSIS
Clinical trials for SECONDARY MYELOFIBROSIS explained in plain language.
Never miss a new study
Get alerted when new SECONDARY MYELOFIBROSIS trials appear
Sign up with your email to follow new studies for SECONDARY MYELOFIBROSIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo may reduce transplant complications in blood cancer patients
Disease control CompletedThis study tested whether adding the drug itacitinib to standard medications (tacrolimus and sirolimus) could help prevent graft-versus-host disease (GVHD) in 59 people with blood cancers like leukemia or myelodysplastic syndrome who received a donor stem cell transplant. GVHD oc…
Matched conditions: SECONDARY MYELOFIBROSIS
Phase: PHASE2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 17, 2026 02:05 UTC
-
New combo therapy shows promise for rare bone marrow cancer
Disease control CompletedThis study looked at whether giving a JAK inhibitor drug before a donor stem cell transplant helps people with myelofibrosis, a serious bone marrow disorder. 61 patients received the drug ruxolitinib before their transplant. The goal was to improve survival and reduce complicatio…
Matched conditions: SECONDARY MYELOFIBROSIS
Phase: PHASE2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated May 17, 2026 01:51 UTC
-
New combo therapy offers hope for hard-to-treat bone marrow cancer
Disease control CompletedThis study tested a combination of two drugs, fedratinib and nivolumab, in 30 adults with myelofibrosis (a type of bone marrow cancer) whose disease did not respond well to standard JAK-inhibitor therapy. The goal was to see if the combination could shrink the spleen, improve sym…
Matched conditions: SECONDARY MYELOFIBROSIS
Phase: PHASE2 • Sponsor: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest • Aim: Disease control
Last updated May 04, 2026 16:19 UTC